Table 2.

Summary ORs for various contrasts of the XRCC1 codon 399 and codon 194 polymorphisms and cancer risk

Ethnicity/contrastOR (%95 CI)ComparisonsXRCC1 codon 399
XRCC1 codon 194
Gln/Gln vs Arg/ArgOR (%95 CI) Gln/Gln vs Arg/Gln + Arg/ArgComparisonsOR (%95 CI) Gln/Gln + Arg/Gln vs Arg/ArgComparisonsOR (%95 CI) Trp/Trp + Arg/Trp vs Arg/ArgComparisons
Asian1.16 (0.98-1.38)131.18 (1.00-1.40)131.00 (0.92-1.09)130.91 (0.78-1.05)7
European0.96 (0.78-1.19)*160.98 (0.80-1.19)*160.99 (0.91-1.07)160.96 (0.78-1.18)9
African1.43 (0.68-2.99)51.24 (0.59-2.60)51.45 (1.13-1.88)50.68 (0.44-1.04)4
Mixed ethnicity0.98 (0.83-1.15)91.00 (0.86-1.17)90.96 (0.87-1.07)90.85 (0.70-1.03)5
Total1.02 (0.90-1.14)*431.03 (0.92-1.15)*431.00 (0.95-1.05)430.89 (0.81-0.98)25
Breast cancer1.10 (0.96-1.27)91.09 (0.96-1.25)91.03 (0.95-1.12)90.95 (0.81-1.11)8
Lung cancer1.11 (0.92-1.34)81.14 (0.95-1.37)80.98 (0.88-1.10)80.87 (0.67-1.14)3
Gastroesophageal cancer0.82 (0.58-1.15)40.86 (0.61-1.20)40.88 (0.74-1.05)40.86 (0.72-1.03)4
Head and neck cancer1.13 (0.81-1.58)41.20 (0.87-1.65)40.95 (0.78-1.16)40.85 (0.59-1.23)3
Bladder cancer0.90 (0.64-1.26)40.87 (0.64-1.20)41.03 (0.84-1.25)4
Other carcinoma0.94 (0.67-1.33)*80.95 (0.70-1.29)*81.00 (0.82-1.22)*80.80 (0.58-1.10)5
Total1.01 (0.90-1.14)*371.03 (0.92-1.15)*371.00 (0.95-1.05)370.89 (0.81-0.98)22
  • * Random effect estimate.

  • Including cancers of colorectal, malignant melanoma, pancreatic adenocarcinoma, nonmelanoma skin, myeloblastic leukemia, hepatocellular, malignant lymphomas, and prostate for Arg399Gln polymorphism; and cancers of colorectal, malignant melanoma, bladder, myeloblastic leukemia, and prostate for Arg194Trp polymorphism.